Bringing the Oncology Community Together

Thalidomide Added to Chemoradiotherapy Shows No Benefit as Lung Cancer Treatment

The addition of thalidomide to chemoradiotherapy provides no survival benefit and increases toxicity in patients with unresectable stage III non-small cell lung cancer.

Oncology & Biotech News   >   Clinical Trial Reports

Going Beyond the Label: Targeted Therapies Present New Questions in Clinical Use

The long-sought aim of treating malignant disease by targeting particular molecular abnormalities is becoming a reality in an increasing number of clinical settings.

Oncology Live   >   From the Editor

Many Patients Continue to Smoke After Cancer Diagnosis

Being newly diagnosed with lung or colorectal cancer is often not sufficient to motivate cigarette smokers to quit.

Oncology & Biotech News   >   Clinical Trial Reports

Personalized Medicine: A Promising Future in Oncology Practice

This issue of Contemporary Oncology includes a focus on 2 challenging situations: management of metastatic TNBC and of advanced stage NSCLC.

Contemporary Oncology   >   From the Editor

Therapy of Non-Small Cell Lung Cancer: Past, Present, and Future

New and relevant studies are examining the role of histology, biomarkers, and growth factor receptor inhibitors in the treatment of NSCLC.

Contemporary Oncology   >   Articles

Support for LDCT Screenings of Heavy Smokers Is Growing

The concept of screening people at high risk for developing lung cancer with low-dose computed tomography continues to gain support in the oncology community.

Oncology Live   >   Specialty Focus

Examining Crizotinib's Potential Uses

The development of crizotinib has helped crystallize a relatively rare molecular subset of NSCLC and holds the potential for wider use in treating patients with the disease.

Oncology Live   >   Specialty Focus

Preoperative Chemotherapy Shows Promise in Early Lung Cancer

Preoperative gemcitabine plus cisplatin followed by radical surgery is feasible, tolerable, and active in patients with early-stage non-small cell lung cancer.

Oncology & Biotech News   >   Clinical Trial Reports

Five Questions for Jill M. Siegfried, PhD

Jill M. Siegfried, PhD, is an investigator into the role of growth factors and hormones in the development and growth of lung cancer.

Oncology Live   >   Pathways

Pursuing an Ethic of Service: Lung Cancer Researcher Noted for Drug Discovery, Charitable Works

An interview with Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, who has dedicated the past 30 years to helping patients with lung cancer.

Oncology Live   >   Profiles in Research

Radiation Therapy After Surgery Shows No Survival Benefit for Elderly Lung Cancer Patients

Many older patients with stage III lung cancer who received radiation therapy fared no better than those who did not receive radiation therapy.

  >   Web Exclusives

Changing Paradigms for NSCLC in Personalized Therapy Era

With the discovery of mutation drivers for NSCLC--including EGFR, KRAS, and EMLA 4-ALK--targeted therapies directed to those mutations are beginning to make a difference.

Oncology & Biotech News   >   Conference Highlights

Continuing Chemotherapy to Near Death Offers No Benefits in Older Patients With Advanced Lung Cancer

An aggressive approach to care involving the continuation of chemotherapy within 2 weeks of death does not improve survival in elderly patients with metastatic NSCLC.

Oncology & Biotech News   >   Clinical Trial Reports

SCLC on the Wane, but Difficult to Treat

Patients with limited and extensive SCLC show incremental gains with different treatment strategies but so far novel agents have failed to make a difference in outcomes.

Oncology & Biotech News   >   Conference Highlights

No Survival Advantage for High-Dose Radiation Versus Standard-Dose Radiation in Stage III NSCLC

High-dose radiation was no better than standard-dose radiation given concurrently with chemotherapy in extending survival of patients with advanced unresectable NSCLC.

Oncology & Biotech News   >   Conference Highlights

Patients With Lung Cancer Often Receive Excess Radiation

Patients undergoing lung resection for NSCLC are frequently exposed to a higher dose of radiation than that which has been deemed safe for healthcare workers.

Oncology & Biotech News   >   Clinical Trial Reports

Biomarker Identifies Patients With Advanced Lung Cancer Who Will Gain Most From Add-On Cetuximab

Investigators reported that high tumor EGFR expression is a predictive biomarker that defines patients with advanced NSCLC who are most likely to derive a survival benefit from the addition of cetuximab to platinum-based, first-line chemotherapy.

Oncology & Biotech News   >   Clinical Trial Reports

Hospitals for Vulnerable Patients Less Likely to Provide Optimal Lung Cancer Care

New data show that patients treated for lung cancer at high safety-net burden hospitals undergo curative-intent surgery significantly less often than individuals treated at low safety-net burden facilities.

Oncology & Biotech News   >   Clinical Trial Reports

5 Questions for Martin Steffen, MD, PhD

Martin Steffen, MD, PhD, developed phosphorylation signatures that discriminate between lung tumors and normal lung, and is developing signatures for the prediction of therapy response.

Oncology Live   >   Pathways

Maintenance Therapy With Bevacizumab/Pemetrexed Appears Superior to Bevacizumab Alone

Maintenance therapy with bevacizumab plus pemetrexed achieved a 4-month benefit in progression-free survival (PFS) versus bevacizumab maintenance therapy alone.

Oncology & Biotech News   >   Conference Highlights